MedElevator
Войти в исследования Retina (Philadelphia, Pa.) · 2026
PLAQUE RADIOTHERAPY FOR POSTERIOR UVEAL MELANOMA IN 4,000 EYES: Risk Factors for ≥15-Letter Visual Acuity Loss in the Pre-Anti-VEGF Era.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shields Carol L, Medina Robert J, Sener Hidayet, Botros Salaam, Choudhury Rehan, Khan Ayra, Gandhi Pranali, Miller Evelyn G, Attaseth Taweevat, Lally Sara E, Shields Jerry A
Аннотация
PURPOSE: To evaluate clinical factors that lead to ≥15-letter visual acuity loss following plaque radiotherapy of posterior uveal melanoma (PUM) in the pre-anti-vascular endothelial growth factor (anti-VEGF) era.
METHODS: The authors reviewed data on 4,000 consecutive patients with plaque-irradiated PUM managed between May 1976 and November 2008 to identify parameters predictive of ≥15-letter vision loss.
RESULTS: Data included median patient age (60 years), diabetes mellitus (11%), median tumor diameter (11.0 mm) and thickness (4.5 mm), and median distance to optic disk (4.0 mm) and foveola (3.0 mm). Kaplan-Meier analyses revealed ≥15-letter loss at 1 versus 3 versus 5 versus 10 years in 30% versus 60% versus 73% versus 82% of patients. Multivariate analyses revealed factors predictive of ≥15-letter loss included greater tumor thickness ( P < 0.01, hazard ratio [HR] 1.14), shorter distance to foveola ( P < 0.01, HR 0.93), greater radiation dose to foveola ( P < 0.01, HR 1.01) and lens ( P < 0.01, HR 1.01), and presence of diabetes mellitus ( P < 0.01, HR 1.11). For small PUM, multivariate risk factors included older age ( P < 0.01), diabetes mellitus ( P < 0.01), and shorter distance to foveola ( P < 0.02); for medium PUM, risk factors included greater tumor thickness ( P < 0.01), shorter distance to foveola ( P < 0.01), and less (but shorter) radiation dose to foveola ( P < 0.01); for large PUM, risk factors included greater tumor thickness ( P < 0.01) only.
CONCLUSION: In the pre-anti-VEGF days, following treatment of PUM with plaque radiotherapy, clinical and treatment factors predictive of ≥15-letter visual acuity loss included greater tumor thickness, shorter distance to foveola, greater radiation dose to foveola and lens, and presence of diabetes mellitus.
METHODS: The authors reviewed data on 4,000 consecutive patients with plaque-irradiated PUM managed between May 1976 and November 2008 to identify parameters predictive of ≥15-letter vision loss.
RESULTS: Data included median patient age (60 years), diabetes mellitus (11%), median tumor diameter (11.0 mm) and thickness (4.5 mm), and median distance to optic disk (4.0 mm) and foveola (3.0 mm). Kaplan-Meier analyses revealed ≥15-letter loss at 1 versus 3 versus 5 versus 10 years in 30% versus 60% versus 73% versus 82% of patients. Multivariate analyses revealed factors predictive of ≥15-letter loss included greater tumor thickness ( P < 0.01, hazard ratio [HR] 1.14), shorter distance to foveola ( P < 0.01, HR 0.93), greater radiation dose to foveola ( P < 0.01, HR 1.01) and lens ( P < 0.01, HR 1.01), and presence of diabetes mellitus ( P < 0.01, HR 1.11). For small PUM, multivariate risk factors included older age ( P < 0.01), diabetes mellitus ( P < 0.01), and shorter distance to foveola ( P < 0.02); for medium PUM, risk factors included greater tumor thickness ( P < 0.01), shorter distance to foveola ( P < 0.01), and less (but shorter) radiation dose to foveola ( P < 0.01); for large PUM, risk factors included greater tumor thickness ( P < 0.01) only.
CONCLUSION: In the pre-anti-VEGF days, following treatment of PUM with plaque radiotherapy, clinical and treatment factors predictive of ≥15-letter visual acuity loss included greater tumor thickness, shorter distance to foveola, greater radiation dose to foveola and lens, and presence of diabetes mellitus.